News

The screening of diabetics for retinopathy has recently become reimbursable in the US, the company noted in its news release, and the approval comes after positive Phase 3 clinical trial earlier this year.

Being able to visualize and evaluate the retinal periphery provides a better understanding of the disease status and supports a better treatment decision.

Prevent Blindness will provide TED educational materials, promote awareness, and offer unique art therapy program for patients and care partners.

By placing the chin on the chinrest, Nidek’s NT-1p automatically detects the position of the eyes and begins measurement without pressing any buttons.

Corneal cross-linking (CXL) is improving all the time, although all protocols retain the basic requirements for oxygen, riboflavin and UV light. Recent developments mean that CXL at the slit lamp is feasible, which will improve access to the procedure.

While the advent of anti-VEGF therapies resulted in substantially better outcomes in this patient population, the results can vary substantially among patients.

David Eichenbaum, MD, FASRS, shared difficult cases of diabetic macular edema (DME) and age-related macular degeneration (AMD) and insights into patient care.

According to UC Davis researchers, more needs to be done for the field to reflect ethnic and racial diversity across the country.

According to the university, the grant will support examining impact of pain and inflammation on eye’s surface and possible link to diseases.

Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.

This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.

According to the company, compounded formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-approved drug products. The prescriptions will be dispensed through Harrow’s wholly owned subsidiary, ImprimisRx.

A new study of albino mice spotlights how the neural circuitry of vision is established, and how it can go wrong.

According to the company, the primary safety endpoint was achieved at all timepoints with all doses well-tolerated and no treatment-related our serious adverse events.

According to a study, use is linked to a lower prevalence of age-related macular degeneration in European populations.

The deal with FamyGem Life Sciences covers the development and commercialization of Nyxol eye drops for the reversal of mydriasis, presbyopia and night vision issues.

OPT-302 in combination with standard-of-care anti-VEGF-A agents shown to improve visual acuity, anatomic endpoints.

The company said it plans to generate clinical data aiming to demonstrate the potential retinal benefits of NCX 470 in order to add significant therapeutic value to the product profile in glaucoma.

Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its uniquely talented team, the strength of Tyrvaya nasal spray and its ophthalmology pipeline.

A study demonstrates that high-resolution imaging with adaptive optics may be a useful method of assessing integrity of the cone mosaic following macular hole repair.

Every football fan knows the scrutiny that NFL game officials are put under every game day, and now a group of ophthalmologists is trying to ensure they can perform at their best each weekend.

In both patients and controls, investigators measured retinal nerve fiber layer thickness, foveal avascular zone area, and vessel density in the superficial capillary plexus, deep capillary plexus, and radial peripapillary capillary plexus.

Combining ECP with vitrectomy can reduce medication use following the procedure and in some cases avoid the need for further surgery.

According to investigators, findings may underscore the need for sleep therapy in patients at risk for glaucoma, and frequent eye checkups for patients who are poor sleepers.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

An end-of-week review of retina news and stories from October 29-November 3, 2022.

According to Apellis Pharmaceuticals, the submission will be a Major Amendment to the NDA, extending the review period by three months with an expected PDUFA target action date in February.